Holen Sie sich die Stockscreener-App
9.35
3.31%
-0.32
Vorhandelsmarkt:
9.47
0.12
+1.28%
Alpha Tau Medical Ltd Aktie (DRTS) Neueste Nachrichten
H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA trial clearance - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Alpha Tau Medical: A Lot Of Shots On Goal (NASDAQ:DRTS) - Seeking Alpha
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control - The Manila Times
Alpha Tau (NASDAQ: DRTS) gets FDA clearance to complete REGAIN glioblastoma trial enrollment - Stock Titan
Alpha Tau Receives FDA Clearance to Complete Enrollment in - GlobeNewswire
Alpha Tau Medical sets up catalyst-rich 2026 as key cancer trial data nears - MSN
Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Insider Sell: Raphi Levy Sells 32,500 Shares of Alpha Tau Medica - GuruFocus
Alpha Tau Medical (DRTS) CFO Levy Raphi sells 32,500 shares in open-market trades - Stock Titan
Alpha Tau,Tolmar Team Up to Bring Alpha DaRT Therapy to U.S. Prostate Cancer Patients - Imaging Technology News
[144] Alpha Tau Medical Ltd. SEC Filing - Stock Titan
Alpha Tau Medical and Tolmar partner to commercialise Alpha DaRT prostate cancer therapy in the US - Health Tech World
H.C. Wainwright Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Alpha Tau Medical Rises on Tolmar Deal to Commercialize Prostate Cancer Therapy - Moomoo
Alpha Tau teams with Tolmar on lucrative prostate cancer dealGlobes - Globes - Israel Business News
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing - Yahoo Finance
Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy - Moomoo
Alpha Tau Strikes 20-Year U.S. Prostate Cancer Commercialization and $20 Million Equity Deal With Tolmar - TipRanks
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients - The Manila Times
Alpha Tau (DRTS) lands Tolmar partnership with $20M equity and milestones - Stock Titan
New prostate cancer radiation option backed by $35M Alpha Tau–Tolmar deal - Stock Titan
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial data - Investing.com UK
Number of shareholders of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer - Moomoo
Alpha Tau Posts Strong Pancreatic Cancer Survival Data for Alpha DaRT at 2026 ASCO - TipRanks
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - The Manila Times
Alpha Tau trial links one-time pancreatic treatment to 11‑month survival - Stock Titan
Pancreatic survival data highlight Alpha Tau (NASDAQ: DRTS) Alpha DaRT trials - Stock Titan
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears - Yahoo Finance
DRTS Initiated Coverage by BarclaysRating Overweight with Tar - GuruFocus
DRTSW Holds Above Key Support After Modest DeclineWatchlist Stock Ideas - The Legal Advocate
DRTS: Key cancer trials advance with pivotal data expected in 2026; strong financial position maintained - TradingView
Barclays Initiates Alpha Tau Medical With Overweight Rating, $15 Price Target - marketscreener.com
Barclays initiates Alpha Tau Medical stock with overweight rating By Investing.com - Investing.com Nigeria
Barclays initiates Alpha Tau Medical stock with overweight rating - Investing.com
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
Alpha Tau Medical (DRTS) Sheds 2.70% as Stock Tests Key Support ZoneValue Factor - thelegaladvocate.com
Alpha Tau Medical (DRTS) Slides 8.4% as Shares Test Support LevelsScalping Stock Signals - thelegaladvocate.com
Alpha Tau Medical stock surges as interim brain tumor trial data sparks rally - MSN
DRTS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Alpha Tau Medical shares early Regain data: 2 complete responses in glioblastoma study - MSN
H.C. Wainwright reiterates Buy on Alpha Tau stock, $15 target - Investing.com India
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):